Last reviewed · How we verify
NCT06118450: FlashIV
Clinical Trial for Evaluating the Effectiveness and Safety of Online caIMR in STEMI Patients
trial testing Non-intervention in Microvascular Coronary Artery Disease in 335 participants. Status unknown.
28 February 2025
Quick facts
| Lead sponsor | The Affiliated Hospital of Xuzhou Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 335 |
| Start date | 1 November 2023 |
| Primary completion | 28 February 2025 |
| Estimated completion | 31 May 2025 |
| Sites | 8 locations across China |
Drugs / interventions tested
- Non-intervention (non-intervention) — full drug profile →
Conditions studied
- Microvascular Coronary Artery Disease — all drugs for Microvascular Coronary Artery Disease →
- STEMI — all drugs for STEMI →
Sponsor
The Affiliated Hospital of Xuzhou Medical University
Who can join
Adults 18 to 80, any sex, with Microvascular Coronary Artery Disease or STEMI. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite the success of restoration of epicardial blood flow by the primary percutaneous coronary intervention (PPCI), approximately a half of patients with ST-segment elevation myocardial infarction (STEMI) have failed myocardial reperfusion, as reflected by microvascular obstruction (MVO) and intramyocardial haemorrhage (IMH). The coronary angiography-derived index of microvascular resistance (caIMR) is a brand new method for assessing coronary microcirculation in ischemia and no obstructive coronary artery disease (INOCA). In this trial, the investigators aim to verify the safety and effectiveness of caIMR in STEMI who underwent primary PCI. The investigators will immediately measure the caIMR of patients who successfully underwent pPCI, and combine the caIMR with the long-term prognosis, to verify the prognostic performance of caIMR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06118450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Non-intervention
Trials testing the same drug.
- NCT06608108 — The Clinical Efficacy of CT-Guided All-in-One Adaptive Emergency Radiotherapy for Spinal Cord Compression Caused by Spin · not yet recruiting
- NCT06271070 — Analysis of Correlation Between Skin Carotenoid Level and Basic Indicators of Health Status Related to Lifestyle in Viet · completed
- NCT06216782 — Exploring the Frontiers of Neoadjuvant Therapy for Lung Cancer: a Prospective Observational Real-world Study · recruiting
- NCT04295057 — Register of Therapeutical Patients Over 60 Years · unknown
- NCT05480189 — Effect of Zoledronic Acid Treatment on Bone-related Events in Breast Cancer Patients With Bone Metastases: a Prospective · not yet recruiting
Other recruiting trials for Microvascular Coronary Artery Disease
Currently open trials in the same condition.
- NCT05492110 — Coronary Sinus Reducer Implantation in Patients With Ischaemia and Non-obstructed Coronary Arteries and Coronary Microva · NA · recruiting
- NCT04541797 — Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozi · NA · active not recruiting
- NCT04827498 — Myocardial Ischemia Without Obstructive Coronary Stenoses · recruiting
Other The Affiliated Hospital of Xuzhou Medical University trials
Trials by the same sponsor.
- NCT06683131 — Effectiveness of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Initiation Before Percutaneous Coronary · Phase 4 · not yet recruiting
- NCT07295366 — Early Administration of PCSK9 Inhibitors After Thrombectomy for Atherosclerotic Acute Ischemic Stroke: A Randomized Cont · Phase 4 · recruiting
- NCT07285395 — AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study · Phase 1 · recruiting
- NCT07301372 — Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemi · Phase 4 · recruiting
- NCT07133776 — Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Di · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06118450 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Hospital of Xuzhou Medical University
- Last refreshed: 8 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06118450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing